ProCE Banner Activity

Expert Treatment Guidance for Myelodysplastic Syndromes

Tool

Use this Interactive Decision Support Tool to compare your approach for treating patients with myelodysplastic syndromes with the strategies recommended by 5 renowned experts.

 

Released: May 09, 2022

Begin Activity

Share

Faculty

Amy E. DeZern

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Rami Komrokji

Rami Komrokji, MD

Professor
Department of Oncologic Sciences
University of South Florida
Vice Chair
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Daniel Pollyea

Daniel Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Michael Savona

Michael Savona, MD

Chief
Hematology, Cellular Therapy and Stem Cell Transplantation
Vanderbilt University School of Medicine
Nashville, Tennessee

Amer Zeidan

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Novartis Pharmaceuticals Corporation and Taiho Oncology, Inc.

AbbVie

Bristol Myers Squibb

Gilead Sciences, Inc.

Novartis Pharmaceuticals Corporation

Taiho Oncology Inc

Faculty Disclosure

Primary Author

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from Bristol-Myers Squibb, CTI BioPharma, Geron, Novartis, and Taiho.

Rami Komrokji, MD

Professor
Department of Oncologic Sciences
University of South Florida
Vice Chair
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Rami Komrokji, MD: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, CTI BioPharma, Geron, Gilead Sciences, Jazz, Novartis, PharmaEssentia, Servier, Taiho, Takeda.

Daniel Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Daniel Pollyea, MD, MS: consultant/advisor/speaker: AbbVie, Arcellx, AstraZeneca, BeiGene, BerGen Bio, Bristol-Myers Squibb, Genentech, Hibercell, Immunogen, Jazz, Kura, LINK, Magenta, Medivir, Novartis, Qihan, Ryvu, Syros, Zentalis; researcher: AbbVie, Bristol-Myers Squibb, Karyopharm, Teva; data and safety monitoring boards: Aptevo, Glycomimetics.

Michael Savona, MD

Chief
Hematology, Cellular Therapy and Stem Cell Transplantation
Vanderbilt University School of Medicine
Nashville, Tennessee

Michael R. Savona, MD: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, CTI, Forma, Geron, Karyopharm, Novartis, Ryvu, Sierra Oncology, Taiho, Takeda; researcher: Astex, Incyte, Takeda; ownership interest: Karyopharm and Ryvu.

Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Amer Zeidan, MBBS: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiff Oncology, Celgene, Geron, Incyte, Medimmune, Novartis, Otsuka, Pfizer, Shattuck Labs, Takeda, Trovagene; consultant: AbbVie, Acceleron, Agios, ALX Oncology, Amgen, Aprea, Astellas, BeyondSpring, Biocryst, Bristol-Myers Squibb, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Foran, Genentech, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Seattle Genetics, Servier, Syndax, Syros, Taiho, Takeda, Trovagene, Tyme.

Additional Information

Program Medium

This program has been made available online.